A CT‐based radiomics model to predict subsequent brain metastasis in patients with ALK‐rearranged non–small cell lung cancer undergoing crizotinib treatment
Abstract Background Brain metastasis (BM) comprises the most common reason for crizotinib failure in patients with anaplastic lymphoma kinase (ALK)‐rearranged non–small cell lung cancer (NSCLC). We hypothesize that its occurrence could be predicted by a computed tomography (CT)‐based radiomics model...
Main Authors: | Yongluo Jiang, Yixing Wang, Sha Fu, Tao Chen, Yixin Zhou, Xuanye Zhang, Chen Chen, Li‐na He, Wei Du, Haifeng Li, Zuan Lin, Yuanyuan Zhao, Yunpeng Yang, Hongyun Zhao, Wenfeng Fang, Yan Huang, Shaodong Hong, Li Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14386 |
Similar Items
-
Fatal Haemoptysis Associated with Dramatic Response to Crizotinib in an ALK-Rearranged Lung Adenocarcinoma
by: Elodie Mussat, et al.
Published: (2016-03-01) -
The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01) -
Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
by: Ruiying Zhao, et al.
Published: (2022-11-01) -
Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
by: Chuangzhou Rao, et al.
Published: (2022-09-01) -
Clinical Efficacy of Crizotinib in Advanced ALK Positive
Non-small Cell Lung Cancer
by: Jing ZHAO, et al.
Published: (2015-10-01)